

Alessandro Loglio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1447994/publications.pdf>

Version: 2024-02-01

60
papers

1,231
citations

566801

15
h-index

377514

34
g-index

60
all docs

60
docs citations

60
times ranked

1740
citing authors

#	ARTICLE	IF	CITATIONS
1	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
2	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 615-625.	1.8	204
3	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
4	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
5	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , 2015, 63, 1118-1125.	1.8	74
6	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
7	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (<sc>NUC</sc>). <i>Liver International</i> , 2017, 37, 45-51.	1.9	65
8	Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. <i>Journal of Hepatology</i> , 2019, 71, 834-839.	1.8	53
9	Safety and effectiveness of up to 3 years™ bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 464-469.	1.8	48
10	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , 2020, 40, 1987-1996.	1.9	44
11	Treatment of hepatitis B: Is there still a role for interferon?. <i>Liver International</i> , 2018, 38, 79-83.	1.9	40
12	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 783-793.	1.8	33
13	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	2.9	21
14	Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. <i>Journal of Hepatology</i> , 2018, 68, 195-198.	1.8	18
15	Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. <i>Cell Reports Medicine</i> , 2020, 1, 100060.	3.3	18
16	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 733-744.	1.9	18
17	A <sc>STAT</sc>4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 564-573.	1.9	17
18	Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 153-161.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.	1.9	11
20	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 419-424.	0.4	9
21	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019, 39, 484-493.	1.9	9
22	<i>rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-α-treated HBeAg-negative chronic hepatitis B patients.</i> <i>Liver International</i> , 2018, 38, 417-423.	1.9	8
23	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogeneic hematopoietic stem cell transplantation for hematological malignancies: two case reports. <i>Haematologica</i> , 2017, 102, e423-e426.	1.7	7
24	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 431-439.	1.9	7
25	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , 2020, 52, 1164-1169.	0.4	7
26	How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?. <i>Hepatology Communications</i> , 2020, 4, 5-7.	2.0	6
27	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5
28	Novel Therapies That May Cure Chronic Hepatitis B Virus. <i>Clinics in Liver Disease</i> , 2021, 25, 875-899.	1.0	5
29	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 464-474.	1.0	4
30	Hepatitis D – how is the fight against this foe going?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 169-171.	1.3	3
31	SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study. <i>Journal of Hepatology</i> , 2019, 70, e687-e688.	1.8	2
32	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , 2020, 5, .	2.3	2
33	Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study. <i>Digestive and Liver Disease</i> , 2022, 54, S38-S39.	0.4	2
34	High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients. <i>Journal of Hepatology</i> , 2017, 66, S689.	1.8	1
35	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. <i>Current Hepatology Reports</i> , 2018, 17, 502-510.	0.4	1
36	Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting. <i>Digestive and Liver Disease</i> , 2018, 50, 55.	0.4	1

#	ARTICLE	IF	CITATIONS
37	THU-221-Xpert HBV VL, simplifying HBV viral load testing and disease management. <i>Journal of Hepatology</i> , 2019, 70, e262.	1.8	1
38	Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, e62.	0.4	1
39	Hepatocellular carcinoma developing in European patients with prolonged HBV suppression: Biological and clinical features, and outcome. <i>Digestive and Liver Disease</i> , 2016, 48, e48-e49.	0.4	0
40	Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients. <i>Digestive and Liver Disease</i> , 2017, 49, e37.	0.4	0
41	High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.4	0
42	Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients. <i>Digestive and Liver Disease</i> , 2017, 49, e28.	0.4	0
43	Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2017, 49, e29.	0.4	0
44	Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients. <i>Journal of Hepatology</i> , 2017, 66, S689-S690.	1.8	0
45	Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S261.	1.8	0
46	Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. <i>Digestive and Liver Disease</i> , 2018, 50, 11.	0.4	0
47	Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. <i>Digestive and Liver Disease</i> , 2018, 50, 51.	0.4	0
48	Clinical and genetic predictors of HCC occurring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. <i>Journal of Hepatology</i> , 2018, 68, S521-S522.	1.8	0
49	Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting. <i>Journal of Hepatology</i> , 2018, 68, S521.	1.8	0
50	The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compensated caucasian HBV cirrhotics treated with Tenofovir or Entecavir. <i>Journal of Hepatology</i> , 2018, 68, S521.	1.8	0
51	FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e477-e478.	1.8	0
52	PS-079-HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy. <i>Journal of Hepatology</i> , 2019, 70, e51.	1.8	0
53	PS-054-Quantitative antibodies against hepatitis B core antigen differ in NUC suppressed caucasian HbeAG-negative patients compared to patients who achieved either "NUC induced" or "spontaneous" functional cure of HBV. <i>Journal of Hepatology</i> , 2019, 70, e33.	1.8	0
54	Incidence and outcome of portal vein thrombosis in 817 HBV and HCV cirrhotic patients under antiviral treatment: a single center longitudinal study. <i>Digestive and Liver Disease</i> , 2019, 51, e10.	0.4	0

#	ARTICLE	IF	CITATIONS
55	The development of hepatocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years. <i>Digestive and Liver Disease</i> , 2019, 51, e56.	0.4	0
56	Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. <i>Journal of Hepatology</i> , 2020, 73, S861-S862.	1.8	0
57	Tenofovir Alafenamide improves proximal tubular markers in CHB patients long-term treated with Tenofovir Disoproxil Fumarate: A real-life study based on the EASL switching criteria. <i>Digestive and Liver Disease</i> , 2021, 53, S14.	0.4	0
58	Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S617-S618.	1.8	0
59	Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years. <i>Journal of Hepatology</i> , 2020, 73, S586.	1.8	0
60	Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients. <i>Digestive and Liver Disease</i> , 2022, 54, S39-S40.	0.4	0